BRAF and neoplasm: Frasca et al [27] found that the presence of the BRAF V600E mutation in PTC is associated with aggressive tumor behavior and that tumor aggressiveness is independent of tumor size, suggesting that even small BRAF-positive tumors carry a higher risk of progression and invasiveness than BRAF-negative tumors.